Mohini Ranganathan MD
Assistant Professor, Psychiatry, Yale University School of Medicine
Join to View Full Profile
950 Campbell AvePsychiatry Service/116aWest Haven, CT 06516
Phone+1 203-932-5711
Dr. Ranganathan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
SUNY Downstate Health Sciences UniversityResidency, Psychiatry, 2002 - 2005
Calicut Medical CollegeClass of 1999
Certifications & Licensure
CT State Medical License 2006 - 2025
American Board of Psychiatry and Neurology Psychiatry
Clinical Trials
- Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia Start of enrollment: 2009 Feb 01
- Effects of Salvinorin A in Healthy Controls Start of enrollment: 2009 Feb 12
- The Effects of Cannabidiol and ∆-9-THC in Humans Start of enrollment: 2010 Feb 01
- Join now to see all
Publications & Presentations
PubMed
- Sex differences in the acute effects of oral THC: a randomized, placebo-controlled, crossover human laboratory study.Ardavan Mohammad Aghaei, Lia Urban Spillane, Brian Pittman, L Taylor Flynn, Joao P De Aquino
Psychopharmacology. 2024-10-01 - 1 citationsSex Differences in the Acute Effects of Oral THC: A Randomized, Placebo-Controlled, Crossover Human Laboratory Study.Ardavan Mohammad Aghaei, Lia Urban Spillane, Brian Pittman, L Taylor Flynn, Joao P De Aquino
Medrxiv. 2024-03-12 - 2 citationsClinical Outcomes of Intravenous Ketamine Treatment for Depression in the VA Health System.Paul N Pfeiffer, Jamarie Geller, Dara Ganoczy, Jennifer Jagusch, John Carty
The Journal of Clinical Psychiatry. 2024-01-08
Journal Articles
- Association of Ketamine with Psychiatric Symptoms and Implications for Its Therapeutic Use and for Understanding SchizophreniaMohini Ranganathan, John H Krystal, JAMA Network Open
Authored Content
- Association of Ketamine with Psychiatric Symptoms and Implications for Its Therapeutic Use and for Understanding SchizophreniaMay 2020
- Association of Ketamine with Psychiatric Symptoms and Implications for Its Therapeutic Use and for Understanding SchizophreniaMay 2020
Press Mentions
Cannabidiol Drugs Clinical Trial Outcomes and Adverse EffectsFebruary 25th, 2020
Fatty Acid Amide Hydrolase (FAAH) Inhibitor Treatment of Cannabis Use Disorder (CUD) (FAAH-I MULTI)December 29th, 2017
Why Some People Can't Handle Their WeedMay 15th, 2017- Join now to see all
Grant Support
- Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)YALE UNIVERSITY2019–2024
- Effect of Cannabidiol on Microglial Activation and Central Pain-SensitizationYALE UNIVERSITY2019–2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
